Affluent, non-diabetic adults paying $1,000–$2,400/year out of pocket to wear continuous glucose monitors and decode how food, exercise, and stress spike their blood sugar. They want to own their metabolic data before a doctor tells them they have a problem — not treat one they already have.
The OTC CGM market hit $528.2M in 2025 and is growing at 17.1% CAGR through 2035 — FDA clearances for Dexcom Stelo and Abbott Lingo removed the prescription barrier entirely, collapsing the friction that kept wellness users out of the category. (GM Insights, July 2026)
The CDC's 2026 National Diabetes Statistics Report now counts 115.2 million American adults with prediabetes — and 8 in 10 don't know it — creating a massive pool of people who have a personal reason to care about glucose without a clinical diagnosis. (CDC, February 2026)
Entrepreneurs and executives are now the fastest-growing non-diabetic CGM user segment, and the broader biohacking market is projected to grow at 19% CAGR to $216.68B by 2035, pulling premium wellness tools including CGMs into a mainstream performance category. (GlobeNewswire / Astute Analytica, February 2026)
The exact words they type into Google.
Create a free account to unlock the full breakdown — all 3 ideas and every community map on the site.
Free forever. No credit card. Takes 20 seconds.